Rocket Pharmaceuticals, Inc. (RCKT)
RCKT moved a median of -0.02% 30 minutes after news, and -0.33% by the close. How RCKT actually reacts to news — the realized, point-in-time move the market made, measured across 1,202 labeled events over the last three years with zero look-ahead.
RCKT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 1,186 |
| 30-min | -0.02% | 47% | 1,191 |
| 60-min | -0.07% | 48% | 1,193 |
| to close | -0.33% | 44% | 1,179 |
| Middle 50% of RCKT reactions | -1.32% to +1.49% |
|---|---|
| Median reaction (30-min) | -0.02% |
| Measured reactions | 1,202 |
Half of all Rocket Pharmaceuticals, Inc. news events land between -1.32% and +1.49% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RCKT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 14 | -1.39% | 21% | +0.63% |
| Analyst downgrades | 30 | +0.04% | 50% | +0.96% |
| Coverage initiations | 18 | -1.11% | 33% | -0.28% |
| Rating reiterations | 96 | -0.43% | 37% | -0.40% |
| Price-target cuts | 27 | +0.14% | 52% | -0.98% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how RCKT ranks against every other measured name →
That’s how RCKT usually reacts — get an email when it moves on news →Email me when RCKT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RCKT's baseline. Nothing else.
Recent RCKT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference | Press release | Business Wire | +1.80% | +6.31% | |
| Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar | Press release | Business Wire | +1.02% | +3.05% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | +3.47% | |
| Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital | Press release | Business Wire | +0.41% | +3.47% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -3.14% | -6.83% | |
| Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease | Press release | Business Wire | -3.14% | -6.83% | |
| Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | Business Wire | -2.44% | -2.82% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | -2.08% | +6.92% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | -2.40% | +8.95% | |
| Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease | Press release | Business Wire | -2.40% | +8.95% | |
| Form S-8 ROCKET PHARMACEUTICALS, | SEC filing · Form S-8 | SEC EDGAR | -1.38% | +0.55% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +0.87% | +2.03% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +1.13% | +3.38% | |
| Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million | Press release | Business Wire | +1.13% | +3.38% | |
| Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | Business Wire | -1.17% | +0.67% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: May 20 | SEC filing · Form 8-K | SEC EDGAR | -0.69% | +6.87% | |
| Form 10-Q ROCKET PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.58% | -3.71% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +3.58% | -3.71% | |
| Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress | Press release | Business Wire | +3.58% | -3.71% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: Apr 26 | SEC filing · Form 8-K | SEC EDGAR | +0.71% | -5.77% | |
| Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher | Press release | Business Wire | +0.71% | -5.77% | |
| Form ARS ROCKET PHARMACEUTICALS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.16% | +1.16% | |
| Form DEF 14A ROCKET PHARMACEUTICALS, For: May 20 | SEC filing · Form DEF | SEC EDGAR | -1.16% | +1.16% | |
| Form DEFA14A ROCKET PHARMACEUTICALS, | SEC filing · Form DEFA14A | SEC EDGAR | -1.16% | +1.16% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -7.43% | -19.96% | |
| Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) | Press release | Business Wire | -7.43% | -19.96% | |
| Form PRE 14A ROCKET PHARMACEUTICALS, For: May 20 | SEC filing · Form PRE | SEC EDGAR | +3.13% | +6.61% | |
| Form EFFECT ROCKET PHARMACEUTICALS, | SEC filing · Form EFFECT | SEC EDGAR | -1.73% | -4.62% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | -1.73% | -4.62% | |
| Form S-3 ROCKET PHARMACEUTICALS, | SEC filing · Form S-3 | SEC EDGAR | -0.74% | +1.05% | |
| Form 10-K ROCKET PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +10.46% | +9.15% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +10.46% | +9.15% | |
| Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress | Press release | Business Wire | +10.46% | +9.15% | |
| Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | Business Wire | +3.91% | +5.00% | |
| Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +0.00% | +1.14% | |
| Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference | Press release | Business Wire | +0.00% | +1.64% | |
| Form 10-Q ROCKET PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.14% | -2.76% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -4.14% | -2.76% | |
| Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress | Press release | Business Wire | -4.14% | -2.76% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.14% | -1.47% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Rocket Pharmaceuticals, Inc. (RCKT) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.13% | -0.13% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.38% | -0.50% | |
| Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.24% | -4.99% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +0.26% | +8.93% | |
| Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) | Press release | Business Wire | +0.26% | +8.93% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.43% | -0.86% | |
| Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.43% | -0.86% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.31% | -1.24% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: Oct 03 | SEC filing · Form 8-K | SEC EDGAR | +1.10% | -1.25% | |
| Form 8-K ROCKET PHARMACEUTICALS, For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -0.31% | -1.24% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RCKT section they belong to.
Where else RCKT is measured.
RCKT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| IMMUNOMEDICS (IMMU) | 1,213 | -0.08% | 45% |
| Biogen Inc. (BIIB) | 1,208 | -0.01% | 49% |
| Insulet Corporation (PODD) | 1,198 | +0.14% | 55% |
| Invacare Corporation (IVC) | 1,193 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Rocket Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled RCKT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,202 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of RCKT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RCKT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.